Aude-Anais Olijnik

Aude-Anais Olijnik

Auto-generated profile, based on publicly available information

Aude-Anais Olijnik

MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
AKAbdullah O. Khan
Abdullah O. Khan
ARAntonio Rodriguez-Romera
Antonio Rodriguez-Romera
JRJasmeet S. Reyat
Jasmeet S. Reyat
AOAude-Anais Olijnik
Aude-Anais Olijnik
MCMichela Colombo
Michela Colombo
BPBethan Psaila
Bethan Psaila
A lack of models that recapitulate the complexity of human bone marrow has hampered mechanistic studies of normal and malignant hematopoiesis and the validation of novel therapies. Here, we describe a step-wise, directed-differentiation protocol in which organoids are generated from induced pluripotent stem cells committed to mesenchymal, endothelial, and hematopoietic lineages. These 3D structures capture key features of human bone marrow—stroma, lumen-forming sinusoids, and myeloid cells including proplatelet-forming megakaryocytes. The organoids supported the engraftment and survival of cells from patients with blood malignancies, including cancer types notoriously difficult to maintain ex vivo. Fibrosis of the organoid occurred following TGFβ stimulation and engraftment with myelofibrosis but not healthy donor–derived cells, validating this platform as a powerful tool for studies of malignant cells and their interactions within a human bone marrow–like milieu. This enabling technology is likely to accelerate the discovery and prioritization of novel targets for bone marrow disorders and blood cancers. Significance: We present a human bone marrow organoid that supports the growth of primary cells from patients with myeloid and lymphoid blood cancers. This model allows for mechanistic studies of blood cancers in the context of their microenvironment and provides a much-needed ex vivo tool for the prioritization of new therapeutics. See related commentary by Derecka and Crispino, p. 263. This article is highlighted in the In This Issue feature, p. 247

26 March 2024 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
AOAude-Anais Olijnik
Aude-Anais Olijnik
ARAntonio Rodriguez-Romera
Antonio Rodriguez-Romera
ZWZoë C. Wong
Zoë C. Wong
YSYuqi Shen
Yuqi Shen
JRJasmeet S. Reyat
Jasmeet S. Reyat
AKAbdullah O. Khan
Abdullah O. Khan

9 October 2024 in Science Translational Medicine
Verified
Journal Article
Open access
RLRong Li
Rong Li
MCMichela Colombo
Michela Colombo
GWGuanlin Wang
Guanlin Wang
ARAntonio Rodriguez-Romera
Antonio Rodriguez-Romera
CBCamelia Benlabiod
Camelia Benlabiod
BPBethan Psaila
Bethan Psaila
Myeloproliferative neoplasms are stem cell–driven cancers associated with a large burden of morbidity and mortality. Most patients present with early-stage disease, but a substantial proportion progress to myelofibrosis or secondary leukemia, advanced cancers with a poor prognosis and high symptom burden. Currently, it remains difficult to predict progression, and therapies that reliably prevent or reverse fibrosis are lacking. A major bottleneck to the discovery of disease-modifying therapies has been an incomplete understanding of the interplay between perturbed cellular and molecular states. Several cell types have individually been implicated, but a comprehensive analysis of myelofibrotic bone marrow is lacking. We therefore mapped the cross-talk between bone marrow cell types in myelofibrotic bone marrow. We found that inflammation and fibrosis are orchestrated by a “quartet” of immune and stromal cell lineages, with basophils and mast cells creating a TNF signaling hub, communicating with megakaryocytes, mesenchymal stromal cells, and proinflammatory fibroblasts. We identified the β-galactoside–binding protein galectin-1 as a biomarker of progression to myelofibrosis and poor survival in multiple patient cohorts and as a promising therapeutic target, with reduced myeloproliferation and fibrosis in vitro and in vivo and improved survival after galectin-1 inhibition. In human bone marrow organoids, TNF increased galectin-1 expression, suggesting a feedback loop wherein the proinflammatory myeloproliferative neoplasm clone creates a self-reinforcing niche, fueling progression to advanced disease. This study provides a resource for studying hematopoietic cell–niche interactions, with relevance for cancer-associated inflammation and disorders of tissue fibrosis.

9 June 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CBCharlotte K. Brierley
Charlotte K. Brierley
BYBon Ham Yip
Bon Ham Yip
GOGiulia Orlando
Giulia Orlando
JWJeremy Wen
Jeremy Wen
SWSean Wen
Sean Wen
AMAdam J. Mead
Adam J. Mead
Chromothripsis, the chaotic shattering and repair of chromosomes, is common in cancer. Whether chromothripsis generates actionable therapeutic targets remains an open question. In a cohort of 64 patients in blast phase of a myeloproliferative neoplasm (BP-MPN), we describe recurrent amplification of a region of chromosome 21q (‘chr. 21amp’) in 25%, driven by chromothripsis in a third of these cases. We report that chr. 21amp BP-MPN has a particularly aggressive and treatment-resistant phenotype. DYRK1A, a serine threonine kinase, is the only gene in the 2.7-megabase minimally amplified region that showed both increased expression and chromatin accessibility compared with non-chr. 21amp BP-MPN controls. DYRK1A is a central node at the nexus of multiple cellular functions critical for BP-MPN development and is essential for BP-MPN cell proliferation in vitro and in vivo, and represents a druggable axis. Collectively, these findings define chr. 21amp as a prognostic biomarker in BP-MPN, and link chromothripsis to a therapeutic target.

1 July 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
ARAlexandros Rampotas
Alexandros Rampotas
ZWZoë C. Wong
Zoë C. Wong
IGIsaac Gannon
Isaac Gannon
CBCharlotte K. Brierley
Charlotte K. Brierley
YSYuqi Shen
Yuqi Shen
MPMartin Pule
Martin Pule
Targeted immunotherapies have revolutionized outcomes for lymphoid malignancies, but success in myeloid neoplasms is limited by the lack of amenable targets and immunologically hostile tumor microenvironment (TME). Myeloproliferative neoplasms (MPNs) are chronic myeloid blood cancers, a third of which are driven by mutations in calreticulin. Calreticulin mutant protein (mutCALR) binds and activates thrombopoietin receptor (TpoR) and results in the display of the mutCALR-TpoR complex on the extracellular membrane of disease-driving cells, thus exposing a therapeutic vulnerability. Here, we present a chimeric antigen receptor T cell (CAR T cell) therapy that specifically targets mutCALR+ cells, both in vitro and in vivo. The CAR T cell therapy selectively depleted mutCALR+ stem cells in samples from patients with myelofibrosis without affecting healthy stem cells and improved survival in mutCALR leukemia xenograft models. To mimic myelofibrotic marrow, we developed a human “chimeroid” model and showed no decrease in the potency of CAR T cell–mediated target cell killing even in a fibrotic TME. We also devised a method to boost the cell surface expression of mutCALR in CD34+ cells isolated from patients with accelerated/blast phase MPNs (defined as >10% blasts in the peripheral blood or bone marrow), enhancing CAR T cell targeting. This study presents a therapeutic strategy with potential to eradicate mutCALR-driven malignancies and highlights an innovative strategy to evaluate blood cancer–targeting immunotherapies in a relevant TME.

2 July 2026 in Nature Communications
Verified
Journal Article
Open access
SBSanja Brolih
Sanja Brolih
HAHafiz Saqib Ali
Hafiz Saqib Ali
CSCaroline Scott
Caroline Scott
AOAude-Anais Olijnik
Aude-Anais Olijnik
HAHazel Aitkenhead
Hazel Aitkenhead
PMPeter J. McHugh
Peter J. McHugh
Congenital Dyserythropoietic Anaemia type I (CDA-I) is a rare inherited disorder of erythropoiesis, in which erythroid cells display a unique nuclear phenotype referred to as ‘spongy’ heterochromatin. The molecular basis of CDA-I remains unknown, with most cases of CDA-I caused by mutations in CDAN1 , encoding Codanin-1, or CDIN1 , encoding for Codanin-1-interacting nuclease 1 (CDIN1). To date, very little is known about the function of CDA-I disease proteins and the mechanism by which their associated mutations cause disease. Here, we demonstrate that endogenous CDIN1 interacts with Codanin-1, to form a stable complex. Structural and functional analysis of this complex reveals that the CDIN1-Codanin-1 complex is an RNA nuclease. We shed light on the key mechanistic features of the complex using biochemical and biophysical approaches, complemented by all-atom molecular dynamics (MD) structural simulations. We identify various functional consequences of founder patient mutations on the RNA nuclease activity of CDIN1, providing a framework for understanding the pathophysiology and developing therapeutic strategies for CDA-I.